Top Story

FDA approves label changes for testosterone, anabolic androgenic steroids

October 26, 2016

The FDA approved classwide labeling changes for all prescription testosterone products to alert prescribers to the abuse potential and serious adverse outcomes related to testosterone and anabolic androgenic steroid use.

The changes include a new Warning section alerting prescribers to potential serious adverse outcomes, including those related to cardiovascular and mental health, as well as an updated Abuse and Dependence section. Anabolic androgenic steroids, including testosterone, are considered schedule II drugs under the Controlled Substances Act.

In the Journals Plus

HbA1c, BMI z score affect LDL, non-HDL cholesterol

October 26, 2016
LDL and non-HDL cholesterol are modestly influenced by changes in HbA1c levels and BMI z score in children with type 1 diabetes, and the effects are greater with…
In the Journals Plus

PCI success, complications similar in patients with, without diabetes

October 25, 2016
Patients with diabetes who underwent percutaneous coronary intervention represented nearly half of those undergoing the surgery in a U.S. cohort between 2012 and 2015
Health Care Legislative and Regulatory Update

Boo! PQRS, Value Modifier penalties for 2017 sure to scare you

October 25, 2016
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of…
In the Journals Plus

Menopause increases risk for sleep-disordered breathing

October 25, 2016
As women transition from premenopause through postmenopause, the risk for sleep-disordered breathing increases, longitudinal data suggest. “Our analysis found that…
More News Headlines »

The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars…
More »
Meeting News Coverage

VIDEO: Long-term oral bisphosphonate use mildly increases risk for osteonecrosis of the jaw

September 20, 2016
More »
Cardiometabolic Health Congress

Cardiometabolic Health Congress

CME Video

Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

This activity is supported by an educational grant from Merck & Co.

Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic…
More »
Current Issues
View the Current Issues